{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T03:00:44Z","timestamp":1780282844364,"version":"3.54.0"},"reference-count":67,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP21ek0510034"],"award-info":[{"award-number":["JP21ek0510034"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jtct.2025.03.008","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T16:13:14Z","timestamp":1742055194000},"page":"382.e1-382.e17","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fludarabine Plus Myeloablative Dose of Busulfan Regimen Was Associated with High Nonrelapse Mortality in Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Lymphoma: A Propensity Score-Matched Comparison Study with Fludarabine Plus High-Dose Melphalan"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5530-6133","authenticated-orcid":false,"given":"Akihito","family":"Shinohara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiho","family":"Shindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6143-7906","authenticated-orcid":false,"given":"Satoshi","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8537-2422","authenticated-orcid":false,"given":"Satoshi","family":"Yoshihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hikaru","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Serizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5681-6357","authenticated-orcid":false,"given":"Ayumu","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuta","family":"Katayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4866-9307","authenticated-orcid":false,"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Yoshimitsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-2870","authenticated-orcid":false,"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0995-9405","authenticated-orcid":false,"given":"Eisei","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jtct.2025.03.008_bib0001","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.beha.2017.11.003","article-title":"Novel agents for relapsed and refractory follicular lymphoma","volume":"31","author":"Cheah","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"issue":"5","key":"10.1016\/j.jtct.2025.03.008_bib0002","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.25460","article-title":"Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment","volume":"94","author":"Liu","year":"2019","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.jtct.2025.03.008_bib0003","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13045-020-00914-1","article-title":"Emerging therapies in mantle cell lymphoma","volume":"13","author":"Hanel","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"15","key":"10.1016\/j.jtct.2025.03.008_bib0004","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood-2017-09-772632","article-title":"Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies","volume":"131","author":"Mottok","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2025.03.008_bib0005","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/hon.2591","article-title":"CAR T-cell therapy: full speed ahead","volume":"37","author":"Sermer","year":"2019","journal-title":"Hematol Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2025.03.008_bib0006","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/17474086.2019.1558399","article-title":"Brentuximab vedotin in T-cell lymphoma","volume":"12","author":"Van Der Weyden","year":"2019","journal-title":"Expert Rev Hematol"},{"issue":"20","key":"10.1016\/j.jtct.2025.03.008_bib0007","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2025.03.008_bib0008","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jtct.2025.03.008_bib0009","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1200\/JCO.2010.30.2596","article-title":"Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin\u2019s lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry","volume":"29","author":"van Kampen","year":"2011","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2025.03.008_bib0010","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/hon.2719","article-title":"Outcome of allogeneic hematopoietic stem cell transplantation for mycosis fungoides and S\u00e9zary syndrome","volume":"38","author":"Mori","year":"2020","journal-title":"Hematol Oncol"},{"issue":"5","key":"10.1016\/j.jtct.2025.03.008_bib0011","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.9807","article-title":"Comparison of allogeneic stem cell transplant and autologous stem cell transplant in refractory or relapsed peripheral T-cell lymphoma: a systematic review and meta-analysis","volume":"4","author":"Du","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.jtct.2025.03.008_bib0012","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/s41409-020-01133-5","article-title":"Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome","volume":"56","author":"Castagna","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2025.03.008_bib0013","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/bjh.14879","article-title":"Allogeneic haematopoietic cell transplantation for extranodal natural killer\/T-cell lymphoma, nasal type: a CIBMTR analysis","volume":"182","author":"Kanate","year":"2018","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.jtct.2025.03.008_bib0014","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41409-020-00996-y","article-title":"GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia\/lymphoma","volume":"56","author":"Muranushi","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2025.03.008_bib0015","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1038\/s41409-021-01445-0","article-title":"Impact of conditioning intensity and regimen on transplant outcomes in patients with adult T-cell leukemia-lymphoma","volume":"56","author":"Inoue","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2025.03.008_bib0016","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/bmt.2015.265","article-title":"Early application of related SCT might improve clinical outcome in adult T-cell leukemia\/lymphoma","volume":"51","author":"Fuji","year":"2016","journal-title":"Bone Marrow Transplant"},{"issue":"7","key":"10.1016\/j.jtct.2025.03.008_bib0017","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.3324\/haematol.2020.268839","article-title":"Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend \u201cwhen and for whom\u201d in 2021?","volume":"106","author":"Gagelmann","year":"2021","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.jtct.2025.03.008_bib0018","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood.V49.4.511.511","article-title":"One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation","volume":"49","author":"Thomas","year":"1977","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2025.03.008_bib0019","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood.V70.5.1382.1382","article-title":"Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen","volume":"70","author":"Tutschka","year":"1987","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.jtct.2025.03.008_bib0020","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1056\/NEJM198312013092202","article-title":"Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide","volume":"309","author":"Santos","year":"1983","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jtct.2025.03.008_bib0021","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/sj.bmt.1705770","article-title":"New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2","volume":"40","author":"Chae","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"15","key":"10.1016\/j.jtct.2025.03.008_bib0022","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S1470-2045(15)00200-4","article-title":"Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial","volume":"16","author":"Rambaldi","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2025.03.008_bib0023","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1182\/blood.V91.3.756","article-title":"Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases","volume":"91","author":"Slavin","year":"1998","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2025.03.008_bib0024","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/cncr.29163","article-title":"Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"121","author":"Baron","year":"2015","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.jtct.2025.03.008_bib0025","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1182\/blood.V97.3.631","article-title":"Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation","volume":"97","author":"Giralt","year":"2001","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.jtct.2025.03.008_bib0026","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1001\/jamaoncol.2020.1278","article-title":"Association of reduced-intensity conditioning regimens with overall survival among patients with non-Hodgkin lymphoma undergoing allogeneic transplant","volume":"6","author":"Ghosh","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2025.03.008_bib0027","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12185-015-1907-9","article-title":"Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation","volume":"103","author":"Kanda","year":"2016","journal-title":"Int J Hematol"},{"issue":"1","key":"10.1016\/j.jtct.2025.03.008_bib0028","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12185-015-1894-x","article-title":"Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data)","volume":"103","author":"Atsuta","year":"2016","journal-title":"Int J Hematol"},{"issue":"3","key":"10.1016\/j.jtct.2025.03.008_bib0029","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1532\/IJH97.06239","article-title":"Unification of hematopoietic stem cell transplantation registries in Japan and establishment of the TRUMP System","volume":"86","author":"Atsuta","year":"2007","journal-title":"Int J Hematol"},{"issue":"8","key":"10.1016\/j.jtct.2025.03.008_bib0030","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2025.03.008_bib0031","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.jtct.2025.03.008_bib0032","unstructured":"Leuven E, Sianesi B. PSMATCH2: Stata module to perform full Mahalanobis and propensity score matching, common support graphing, and covariate imbalance testing. EconPapers. 2003; Revised 2018; https:\/\/econpapers.repec.org\/software\/bocbocode\/s432001.htm. Accessed April 1, 2025."},{"issue":"6","key":"10.1016\/j.jtct.2025.03.008_bib0033","first-page":"825","article-title":"1994 consensus conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2025.03.008_bib0034","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/0002-9343(80)90380-0","article-title":"Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients","volume":"69","author":"Shulman","year":"1980","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.jtct.2025.03.008_bib0035","doi-asserted-by":"crossref","first-page":"255","DOI":"10.7326\/0003-4819-118-4-199302150-00003","article-title":"Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients","volume":"118","author":"McDonald","year":"1993","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.jtct.2025.03.008_bib0036","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/00007890-198712000-00011","article-title":"Venoocclusive disease of the liver following bone marrow transplantation","volume":"44","author":"Jones","year":"1987","journal-title":"Transplantation"},{"issue":"282","key":"10.1016\/j.jtct.2025.03.008_bib0037","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"3","key":"10.1016\/j.jtct.2025.03.008_bib0038","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A class of K-sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Stat"},{"issue":"446","key":"10.1016\/j.jtct.2025.03.008_bib0039","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"3","key":"10.1016\/j.jtct.2025.03.008_bib0040","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"16","key":"10.1016\/j.jtct.2025.03.008_bib0041","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1056\/NEJM197504172921605","article-title":"Bone-marrow transplantation (first of two parts)","volume":"292","author":"Thomas","year":"1975","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jtct.2025.03.008_bib0042","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/bmt.2014.269","article-title":"Comparison of non-myeloablative conditioning regimens for lymphoproliferative disorders","volume":"50","author":"Hong","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.jtct.2025.03.008_bib0043","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood.V79.10.2578.bloodjournal79102578","article-title":"Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse","volume":"79","author":"Blaise","year":"1992","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jtct.2025.03.008_bib0044","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.jtct.2025.03.008_bib0045","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/s41409-022-01705-7","article-title":"A randomized phase III study of pretransplant conditioning for AML\/MDS with fludarabine and once daily IV busulfan\u2009\u00b1\u2009clofarabine in allogeneic stem cell transplantation","volume":"57","author":"Andersson","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2025.03.008_bib0046","doi-asserted-by":"crossref","first-page":"483.e1","DOI":"10.1016\/j.jtct.2021.02.031","article-title":"Myeloablative versus reduced-intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic syndromes-long-term follow-up of the BMT CTN 0901 clinical trial","volume":"27","author":"Scott","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.jtct.2025.03.008_bib0047","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1200\/JCO.1995.13.7.1786","article-title":"High-dose intravenous melphalan: a review","volume":"13","author":"Samuels","year":"1995","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2025.03.008_bib0048","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/asheducation-2005.1.384","article-title":"Reduced-intensity conditioning regimens for hematologic malignancies: what have we learned over the last 10 years?","volume":"2005","author":"Giralt","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"2","key":"10.1016\/j.jtct.2025.03.008_bib0049","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1200\/JCO.1997.15.2.660","article-title":"Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma","volume":"15","author":"Moreau","year":"1997","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2025.03.008_bib0050","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.bbmt.2012.08.011","article-title":"Fifty years of melphalan use in hematopoietic stem cell transplantation","volume":"19","author":"Bayraktar","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.jtct.2025.03.008_bib0051","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/cncr.31264","article-title":"Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: a combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR","volume":"124","author":"Sureda","year":"2018","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.jtct.2025.03.008_bib0052","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1182\/blood-2004-02-0414","article-title":"Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS","volume":"104","author":"de Lima","year":"2004","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2025.03.008_bib0053","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/bmt.2016.322","article-title":"Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML\/MDS patients","volume":"52","author":"Andersson","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2025.03.008_bib0054","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00277-015-2349-4","article-title":"Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission","volume":"94","author":"Magenau","year":"2015","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.jtct.2025.03.008_bib0055","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00277-023-05084-x","article-title":"Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation","volume":"102","author":"Kamijo","year":"2023","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.jtct.2025.03.008_bib0056","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.clml.2014.12.016","article-title":"Myeloablative intravenous pharmacokinetically targeted busulfan plus fludarabine as conditioning for allogeneic hematopoietic cell transplantation in patients with non-Hodgkin lymphoma","volume":"15","author":"Ayala","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"10.1016\/j.jtct.2025.03.008_bib0057","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/annonc\/mdx274","volume":"28","author":"Le Bourgeois","year":"2017","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.jtct.2025.03.008_bib0058","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.bbmt.2016.07.006","article-title":"Fludarabine\/busulfan versus fludarabine\/melphalan conditioning in patients undergoing reduced-intensity conditioning hematopoietic stem cell transplantation for lymphoma","volume":"22","author":"Kekre","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2025.03.008_bib0059","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/sj.bmt.1700913","article-title":"BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors","volume":"20","author":"Caballero","year":"1997","journal-title":"Bone Marrow Transplant"},{"issue":"24","key":"10.1016\/j.jtct.2025.03.008_bib0060","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1182\/blood-2013-07-514448","article-title":"Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI","volume":"122","author":"Copelan","year":"2013","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2025.03.008_bib0061","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.bbmt.2016.04.013","article-title":"Intravenous busulfan-based myeloablative conditioning regimens prior to hematopoietic cell transplantation for hematologic malignancies","volume":"22","author":"Pasquini","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2025.03.008_bib0062","doi-asserted-by":"crossref","first-page":"323.e1","DOI":"10.1016\/j.jtct.2022.03.011","article-title":"Myeloablative versus reduced-intensity conditioning with fludarabine\/busulfan for myelodysplastic syndrome: a propensity score-matched analysis","volume":"28","author":"Kurosawa","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1016\/j.jtct.2025.03.008_bib0063","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/bmt.2014.133","article-title":"Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT","volume":"49","author":"Kharfan-Dabaja","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2025.03.008_bib0064","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jtct.2022.03.015","article-title":"Noninfectious pulmonary toxicity after allogeneic hematopoietic cell transplantation","volume":"28","author":"Patel","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"15","key":"10.1016\/j.jtct.2025.03.008_bib0065","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1182\/blood-2012-09-455063","article-title":"How I assess comorbidities before hematopoietic cell transplantation","volume":"121","author":"Sorror","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2025.03.008_bib0066","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.bbmt.2008.11.023","article-title":"Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantation","volume":"15","author":"Pollack","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.jtct.2025.03.008_bib67","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1038\/s41409-020-0803-y","article-title":"Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients","volume":"55","author":"Spyridonidis","year":"2020","journal-title":"Bone Marrow Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725010978?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725010978?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T02:11:00Z","timestamp":1780279860000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725010978"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":67,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S2666636725010978"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.03.008","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fludarabine Plus Myeloablative Dose of Busulfan Regimen Was Associated with High Nonrelapse Mortality in Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Lymphoma: A Propensity Score-Matched Comparison Study with Fludarabine Plus High-Dose Melphalan","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}